FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015808886> ?p ?o ?g. }

• W2015808886 abstract "This study was designed to evaluate the efficacy and toxicity of dose intensifying DHAP (dexamethasone, cytarabine and cisplatin) salvage chemotherapy by adding mitoxantrone with GM-GSF support in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). From March 1992 to January 1995, 22 patients with intermediate and high grade (aggressive) NHL refractory or relapsed after adriamycin containing chemotherapy regimens were treated with M-DHAP+GM-CSF, (dexamethasone 40 mg i.v. days 1-4, cisplatin 100 mg/m2 i.v. by continuous infusion over 24 hours on day 1, cytarabine 2 gm/m2, i.v. every 12 hours for 2 doses on day 2, mitoxantrone 10 mg/m2 i.v. on days 3 and 4 and GM-CSF 250-500 microg/m2 s.c. daily beginning day 5 until absolute neutrophil count recovery. Most patients had poor prognostic factors including primary refractory disease (18/22), bulky disease (12/22), elevated LDH (9/22), or bone marrow involvement (8/22). All 22 patients were evaluable. The overall response rate was 41% (CR 23% and PR 18%). There were three toxic deaths, all related to sepsis. Median progression free survival (PFS) and overall survival (OS) rates were 5.2 months and 11.8 months respectively. At the same time of the analysis two patients were alive after high-dose therapy and bone marrow transplant at 34 and 36 months follow-up and two were alive with disease. The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity. Treatment delays and dose reductions compromised delivering the optimal dose intensity of M-DHAP. A poor prognostic group of patients with refractory or recurrent aggressive lymphoma, many of whom were not eligible for high-dose therapy and stem cell transplantation were treated with repeated cycles of dose intensified DHAP with growth factor support. Although M-DHAP had therapeutic activity even in patients considered to have primary refractory disease, myelosuppression was dose limiting and frequently limited the number of cycles. Therefore, if M-DHAP is to be further evaluated, therapeutic results may be improved further by incorporating strategies to reduce myelotoxicity such as the use of growth factors to reduce platelet transfusion requirements or the use of autologous stem cell support after each cycle." @default.
• W2015808886 created "2016-06-24" @default.
• W2015808886 creator A5002860158 @default.
• W2015808886 creator A5032255536 @default.
• W2015808886 creator A5056927977 @default.
• W2015808886 creator A5069654391 @default.
• W2015808886 date "1999-01-01" @default.
• W2015808886 modified "2023-09-27" @default.
• W2015808886 title "Mitoxantrone-DHAP with GM-CSF: An Active but Myelosuppressive Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma" @default.
• W2015808886 cites W1604637468 @default.
• W2015808886 cites W1605164920 @default.
• W2015808886 cites W1757326868 @default.
• W2015808886 cites W1830057497 @default.
• W2015808886 cites W1830589476 @default.
• W2015808886 cites W1834664850 @default.
• W2015808886 cites W1841420516 @default.
• W2015808886 cites W1847164289 @default.
• W2015808886 cites W1880372716 @default.
• W2015808886 cites W1881397173 @default.
• W2015808886 cites W1911320760 @default.
• W2015808886 cites W1958341727 @default.
• W2015808886 cites W1985916436 @default.
• W2015808886 cites W1988746054 @default.
• W2015808886 cites W2013642593 @default.
• W2015808886 cites W2031683542 @default.
• W2015808886 cites W2059391727 @default.
• W2015808886 cites W2084422893 @default.
• W2015808886 cites W2084782675 @default.
• W2015808886 cites W2098766729 @default.
• W2015808886 cites W2104701261 @default.
• W2015808886 cites W2137920066 @default.
• W2015808886 cites W2273109191 @default.
• W2015808886 cites W2313423582 @default.
• W2015808886 cites W2318772898 @default.
• W2015808886 cites W2339381415 @default.
• W2015808886 cites W4241762497 @default.
• W2015808886 doi "https://doi.org/10.1080/10428199909169617" @default.
• W2015808886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10609790" @default.
• W2015808886 hasPublicationYear "1999" @default.
• W2015808886 type Work @default.
• W2015808886 sameAs 2015808886 @default.
• W2015808886 citedByCount "11" @default.
• W2015808886 crossrefType "journal-article" @default.
• W2015808886 hasAuthorship W2015808886A5002860158 @default.
• W2015808886 hasAuthorship W2015808886A5032255536 @default.
• W2015808886 hasAuthorship W2015808886A5056927977 @default.
• W2015808886 hasAuthorship W2015808886A5069654391 @default.
• W2015808886 hasConcept C121332964 @default.
• W2015808886 hasConcept C126322002 @default.
• W2015808886 hasConcept C141071460 @default.
• W2015808886 hasConcept C142424586 @default.
• W2015808886 hasConcept C143998085 @default.
• W2015808886 hasConcept C181199279 @default.
• W2015808886 hasConcept C185592680 @default.
• W2015808886 hasConcept C2776694085 @default.
• W2015808886 hasConcept C2778041864 @default.
• W2015808886 hasConcept C2778239845 @default.
• W2015808886 hasConcept C2778822529 @default.
• W2015808886 hasConcept C2779338263 @default.
• W2015808886 hasConcept C2779617269 @default.
• W2015808886 hasConcept C2780775027 @default.
• W2015808886 hasConcept C2780923524 @default.
• W2015808886 hasConcept C55493867 @default.
• W2015808886 hasConcept C71924100 @default.
• W2015808886 hasConcept C87355193 @default.
• W2015808886 hasConcept C90924648 @default.
• W2015808886 hasConceptScore W2015808886C121332964 @default.
• W2015808886 hasConceptScore W2015808886C126322002 @default.
• W2015808886 hasConceptScore W2015808886C141071460 @default.
• W2015808886 hasConceptScore W2015808886C142424586 @default.
• W2015808886 hasConceptScore W2015808886C143998085 @default.
• W2015808886 hasConceptScore W2015808886C181199279 @default.
• W2015808886 hasConceptScore W2015808886C185592680 @default.
• W2015808886 hasConceptScore W2015808886C2776694085 @default.
• W2015808886 hasConceptScore W2015808886C2778041864 @default.
• W2015808886 hasConceptScore W2015808886C2778239845 @default.
• W2015808886 hasConceptScore W2015808886C2778822529 @default.
• W2015808886 hasConceptScore W2015808886C2779338263 @default.
• W2015808886 hasConceptScore W2015808886C2779617269 @default.
• W2015808886 hasConceptScore W2015808886C2780775027 @default.
• W2015808886 hasConceptScore W2015808886C2780923524 @default.
• W2015808886 hasConceptScore W2015808886C55493867 @default.
• W2015808886 hasConceptScore W2015808886C71924100 @default.
• W2015808886 hasConceptScore W2015808886C87355193 @default.
• W2015808886 hasConceptScore W2015808886C90924648 @default.
• W2015808886 hasLocation W20158088861 @default.
• W2015808886 hasLocation W20158088862 @default.
• W2015808886 hasOpenAccess W2015808886 @default.
• W2015808886 hasPrimaryLocation W20158088861 @default.
• W2015808886 hasRelatedWork W1804439365 @default.
• W2015808886 hasRelatedWork W1969461242 @default.
• W2015808886 hasRelatedWork W1982093470 @default.
• W2015808886 hasRelatedWork W2041795664 @default.
• W2015808886 hasRelatedWork W2059146719 @default.
• W2015808886 hasRelatedWork W2059391727 @default.
• W2015808886 hasRelatedWork W2084065914 @default.
• W2015808886 hasRelatedWork W2120990323 @default.
• W2015808886 hasRelatedWork W2141295975 @default.
• W2015808886 hasRelatedWork W2156203592 @default.
• W2015808886 hasRelatedWork W2159746531 @default.

• next